Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside ‐1000 (Monofer®) versus ferric carboxy‐maltose (Ferinject®). A single center, cohort study

ConclusionsFerric carboxymaltose is associated with a 75% lower risk on HSRs compared with iron isomaltoside ‐1000 in our population. The presence of a comorbidity raises the likelihood of a HSR with a factor three regardless of the type of intravenous iron infusion. Further research is needed to clarify the underlying mechanism in various patient groups.

https://onlinelibrary.wiley.com/doi/abs/10.1111/bcp.13805?af=R

Source: British Journal of Clinical Pharmacology - November 4, 2018 Category: Drugs & Pharmacology Authors: M.B. Mulder, H.L. Hoek, E. Birnie, A.J.P. Tilburg, E.M. Westerman Tags: ORIGINAL ARTICLE Source Type: research